Navigation Links
Barr Confirms Patent Challenge of Sensipar(R) Tablets, 30mg, 60mg and 90mg
Date:7/29/2008

MONTVALE, N.J., July 29 /PRNewswire-FirstCall/ -- Barr Pharmaceuticals, Inc. (NYSE: BRL) today confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen Inc. in connection with its Sensipar(R) Tablets (cincalcet hydrochloride), 30mg, 60mg and 90mg.

Barr's Abbreviated New Drug Application (ANDA) containing a paragraph IV certification for a generic Sensipar product was received as acceptable for filing by the U.S. Food & Drug Administration (FDA) on March 10, 2008, the first date the FDA could accept an ANDA with a paragraph IV certification for this product. Following receipt of the notice from the FDA that Barr's ANDA had been accepted for filing, Barr notified the New Drug Application (NDA) and patent holder.

On July 25, 2008, Brigham and Women's Hospital Inc., NPS Pharmaceuticals, Inc. and Amgen filed suit in the U.S. District Court for the District of Delaware to prevent Barr from proceeding with the commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act.

Sensipar (cincalcet hydrochloride) had annual sales of approximately $377 million in the U.S., based on IMS sales data for the twelve month period ending May 2008.

About Barr Pharmaceuticals, Inc.

Barr Pharmaceuticals, Inc. is a global specialty pharmaceutical company that operates in more than 30 countries worldwide and is engaged in the development, manufacture and marketing of generic and proprietary pharmaceuticals, biopharmaceuticals and active pharmaceutical ingredients. A holding company, Barr operates through its principal subsidiaries: Barr Laboratories, Inc., Duramed Pharmaceuticals, Inc. and PLIVA d.d. and its subsidiari
'/>"/>

SOURCE Barr Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
2. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
3. Recent Study Confirms Alimentary Healths Bifantis(R) Demonstrates Efficacy in the Treatment of Irritable Bowel Syndrome
4. Barr Confirms Patent Challenge of Focalin(R) XR
5. Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
6. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
7. Icahn Confirms Intention to Nominate Three Directors at Biogen
8. Barr Confirms Patent Challenge of Avodart(R) Soft Gelatin Capsules, 0.5mg
9. PPD Confirms Takedas NDA Filing of Alogliptin with U.S. Food and Drug Administration
10. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
11. Research Confirms Better Oil from New DuPont High Oleic Soybean Trait
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Wis. , May 23, 2013 ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... its research opinion on the company based on ... , Non-Prescription, All Natural Product to ... the Product Outperforms #1 Prescription Competitor , ...
(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...
(Date:5/23/2013)... SAN MARINO, Calif. , May 23, 2013 ... announces today a strategic alliance with DAK Renewable ... increase the corn oil yield. VG Energy is ... Inc. (OTC Pink: VGLS). VG Energy,s ... pathways to increase the oil yield in plants, ...
(Date:5/23/2013)... May 23, 2013 Virobay, Inc. today announced ... has reached an important milestone, as Virobay has now ... a selective cathepsin S inhibitor.   The ... randomized, placebo-controlled study designed to evaluate the safety, tolerability, ... healthy adults. "The initiation of this Phase ...
Breaking Biology Technology:PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 2PuraMed BioScience (PMBS) Issued Alert Based on Market Cap of $721,756 3Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 2VG Energy Enters into a Strategic Alliance with DAK Renewable Research for LipidMax Field Trials 3Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 2Virobay, Inc. initiates a Phase 1 Trial of VBY-036, a compound intended for the treatment of neuropathic pain 3
...  MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, ... and bioimplants processed from human amniotic membrane, announced ... to sell convertible notes and warrants has been ... commenced on October 15, 2011, the Company received ...
... Dec. 27, 2011  While many Americans are resolving to address ... shows that some adults are looking to find answers to ... The survey, which was commissioned by Identigene, the ... Identigene DNA Paternity Test, the only paternity test available at ...
... 27, 2011 Cord Blood America, Inc . ( ... umbilical cord blood stem cell preservation company focused ... families nationwide and internationally, is pleased to announce it has ... Las Vegas laboratory for the National Children,s Leukemia Foundation (NCLF), ...
Cached Biology Technology:MiMedx Group Completes $5,000,000 Private Placement 2MiMedx Group Completes $5,000,000 Private Placement 3Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 2Survey Reveals Paternity Questions Loom for More Than One in 10 Americans 3Cord Blood America Announces Exclusive Agreement With National Children's Leukemia Foundation to Store Stem Cells 2
(Date:5/23/2013)... tight wrapping of genomic DNA around nucleosomes in ... expression. A team of Ludwig-Maximilians-Universitaet (LMU) in Munich ... to be locally displaced from nucleosomes for transcription. ... stored in the cell nucleus, wrapped around disk-shaped ... of four different histone proteins and accommodating two ...
(Date:5/23/2013)... A new report from the Institute of Medicine says ... at least 60 minutes of vigorous or moderate intensity ... half of American youth meet current evidence-based guidelines of ... physical activity daily, according to the report, which was ... for nearly half of their waking hours, the committee ...
(Date:5/23/2013)... of the world,s largest and fastest growing open-access ... Frontiers in Bioengineering and Biotechnology . ... Frontiers in Bioengineering and Biotechnology will ... emerging bioengineering and biotechnology research to be disseminated ... and Biotechnology will provide an open-science and ...
Breaking Biology News(10 mins):Biochemistry: Unspooling DNA from nucleosomal disks 2Schools should provide students with daily physical activity, IOM recommends 2Frontiers launches new open-access journal in Bioengineering and Biotechnology 2
... of Medicine have discovered a novel strategy by which ... to resist the effects of antibiotics known as fluoroquinolones. ... and E. coli, are rapidly becoming resistant to fluoroquinolones. ... John S. Blanchard, the Dan Danciger Professor of Biochemistry ...
... genetics of barley could lead to improved varieties of ... whisky and beer. Scientists funded in part by the ... a new programme to uncover key genes that control ... research, being carried out at the Scottish Crop Research ...
... organisms hidden in caves, such as sponges, play an ... reefs. Indeed they probably play the most important role ... is valuable information for nature conservationists who want to ... coral reefs it is important to understand how both ...
Cached Biology News:Einstein researchers identify new way that bacteria develop resistance to antibiotics 2Whisky fans can drink to crop research 2Hidden sponges determine coral reef's nutrient cycle 2
Rabbit polyclonal to Staphylococcus Enterotoxin E (Biotin) ( Abpromise for all tested applications)....
...
...
... CRF The antibody blocks ... sequence that it was raised ... found in the paraventricular hypothalamic ... colchicine treated 4% FA perfused ...
Biology Products: